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Sepsis is a syndrome related to severe infections. It is defined as the systemic host response to microorganisms in previously
sterile tissues and is characterized by end-organ dysfunction away from the primary site of infection. The normal host response to
infection is complex and aims to identify and control pathogen invasion, as well as to start immediate tissue repair. Both the
cellular and humoral immune systems are activated, giving rise to both anti-inflammatory and proinflammatory responses. The
chain of events that leads to sepsis is derived from the exacerbation of these mechanisms, promoting massive liberation of mediators
and the progression of multiple organ dysfunction. Despite increasing knowledge about the pathophysiological pathways and
processes involved in sepsis, morbidity and mortality remain unacceptably high. A large number of immunomodulatory agents
have been studied in experimental and clinical settings in an attempt to find an efficacious anti-inflammatory drug that reduces
mortality. Even though preclinical results had been promising, the vast majority of these trials actually showed little success in
reducing the overwhelmingly high mortality rate of septic shock patients as compared with that of other critically ill intensive care
unit patients. Clinical management usually begins with prompt recognition, determination of the probable infection site, early
administration of antibiotics, and resuscitation protocols based on “early-goal” directed therapy. In this review, we address the
research efforts that have been targeting risk factor identification, including genetics, pathophysiological mechanisms and strategies
to recognize and treat these patients as early as possible.
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INTRODUCTION
The word sepsis is derived from the Greek term for rot-
ten or “to make putrid”. Sepsis, defined as the systemic host
response to microorganisms in previously sterile tissues, is
a syndrome related to severe infections and is character-
ized by end-organ dysfunction away from the primary site
of infection. To meet the definition of sepsis, patients need
to satisfy at least two of the Systemic Inflammatory Re-
sponse Syndrome (SIRS) criteria in association with hav-
ing a suspected or confirmed infection.1,2,3,4,5 The severity
and mortality increase when this condition is complicated
by predefined organ dysfunction (severe sepsis) and car-
diovascular collapse (septic shock).6
The normal host response to infection is complex, aim-
ing to both identify and control pathogen invasion and start
immediate tissue repair. Both the cellular and humoral im-
mune systems are activated, giving rise to anti-inflamma-
tory and proinflammatory responses. Exacerbating these
mechanisms can cause a chain of events that leads to sep-
sis, promoting massive liberation of mediators and the pro-
gression of multiple organ dysfunction.7
Morbidity and mortality remain unacceptably high de-
spite increasing knowledge about the pathophysiological
pathways and processes involved in sepsis. It still is one
of the most prevalent causes of intensive care units (ICU)
morbidity and mortality worldwide.1,8 More than 750,000
sepsis cases occur in the United States every year, leading
to approximately 220,000 deaths.9,10 Consistent data on the
incidence, outcome and costs of sepsis patients in Brazil
and Latin America are scarce. However, a recent Brazilian
study showed that up to 25% of ICU patients will meet sep-
sis diagnostic criteria during an ICU stay.11 Even with the
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best treatment available, the mortality rates of septic shock
could be as high as 50%1, 6, 8, 9, 11 or up to 75% on longer
follow-ups.12
In an attempt to find an efficacious anti-inflammatory
drug that reduces mortality, a large number of immuno-
modulatory agents have been studied in experimental and
clinical settings. However, the vast majority of these trials
showed little success in reducing the overwhelmingly high
mortality rates of septic shock patients as compared to those
other critically ill ICU patients,9,13,14,15 despite promising
preclinical results. Clinical management usually begins
with prompt recognition, determination of the probable in-
fection site, early administration of antibiotics, and resus-
citation protocols based on “early-goal” directed therapy.1,10
In this review, we address the research efforts that have
been targeting both risk factor identification, including ge-
netics, pathophysiological mechanisms and strategies to
recognize and treat these patients as early as possible.
Definitions
The syndrome currently known as sepsis has had many
definitions over the years.2 In 1991, a consensus confer-
ence organized by the American College of Chest Physi-
cians and the Society of Critical Care Medicine clinically
defined the terms SIRS, sepsis, severe sepsis and septic
shock (Table 1).1,2,3,4 Even though the definition has high
sensitivity and low specificity, it has been helpful in im-
proving patient care, enrollment in clinical trials and com-
munication between ICUs.
A second conference held in 2001 attempted to refine
the definitions, increase specificity by emphasizing prompt
recognition and add a list of common symptoms and signs
of sepsis.2,3,5,10 The current definitions are as follows:
• Infection: pathologic process caused by invasion of nor-
mally sterile tissue, fluid or body cavity by pathogenic
or potentially pathogenic microorganisms.
• Sepsis: documented or suspected infection associated
with any of the systemic inflammatory syndrome signs.
• Severe Sepsis: sepsis complicated by pre-defined organ
dysfunction.
• Septic Shock: sepsis-induced acute circulatory failure
characterized by persistent arterial hypotension despite
adequate volume administration and not explained by
causes other than sepsis.
Besides refining the diagnostic definitions, the 2001
consensus conference brought new insight into sepsis stag-
ing, with the aim of better characterizing disease severity.
The PIRO concept was then introduced (Table 2) with the
idea that these factors would have relevant impact on sep-
sis development and outcome.2,5,10
EPIDEMIOLOGY
Sepsis has been recognized as a major public health
problem in population-based and ICU-based epidemiologi-
cal studies. Two studies have reported the sepsis incidence
in the United States8,9,11,13,14. Briefly, the methodology used
by these reports is primarily based on the International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) codes for principal hospital discharge
diagnosis. The databases are linked with state and national
population data from the US Census for the same year to
generate population-based incidence rates. In order to iden-
Table 1 - Sepsis definitions
1. Systemic Inflammatory Response Syndrome (SIRS). Two or more of
the following: a) temperature (core) > 38.3ºC or < 36ºC; b) heart rate >
90 beats/min; c) respiratory rate > 20 breaths/min, PaCO2 < 32 mm Hg
or need for mechanical ventilation; d) WBC count > 12.000/mm3 or <
4.000/ mm3 or > 10% immature forms (bands).
2. Sepsis is defined as SIRS associated with suspected or confirmed
infection. Positive blood cultures are not necessary16.
3. Severe sepsis is sepsis complicated by a predefined organ dysfunction.
4. Septic shock is cardiovascular collapse related to severe sepsis despite
adequate fluid resuscitation. Hypotension is: systolic blood pressure
(SBP) < 90 mm Hg, mean arterial pressure (MAP) < 65 mm Hg or a
reduction of > 40 mm Hg on baseline SBP.
5. Organ dysfunction criteria are a) hypoxemia (PaO2/FiO2 ratio < 300); b)
acute oliguria (urine output < 0.5 ml/kg/h for 2 h) or creatinine > 2.0
mg/dL; c) coagulopathy (platelet count < 100.000, INR > 1.5 or pTTa >
60 s); d) ileus; e) plasma bilirubin > 4 mg/dL)1, 2, 5, 10.
Table 2 - PIRO concept
Clinical Other tests
P (predisposition) Age, alcohol abuse, steroid or immunosuppressive therapy Immunologic monitoring, genetic factors
I (infection) Site-specific (e.g., pneumonia, peritonitis) X-rays, CT scan, bacteriology
R (response) Malaise, temperature, heart rate, respiratory rate WBC, CRP, PCT, modified APTT
O (organ dysfunction) Arterial pressure, urine output, Glasgow coma score PaO2/FIO2, creatinine, bilirubin, platelets
APTT: Aactivated partial thromboplastin time; CRP: C-reactive protein; CT: Computed tomography; PCT: Procalcitonin; WBC: White blood cell count
Modified from: Vincent JL, Abraham E. The last 100 years of sepsis. Am J Resp Crit Care Med. 2006. 173:256-263.
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tify cases of severe sepsis, the authors selected all cases
with ICD-9 for bacterial or fungal infection and a diagno-
sis of acute organ dysfunction. Then, the authors compared
those patients selected by ICD-9 with the standard clini-
cal criteria for the definitions of severe sepsis9 and sepsis.13
Martin et al.13 estimated the incidence of sepsis in the US
as 240 cases per 100,000 people, and Angus et al.9 reported
300 cases of severe sepsis per 100,000 people. The
inicidence was projected to increase by 1.5% per annum.
The mortality rate reported in these studies was also simi-
lar, ranging from 17.9% for sepsis13 to 28.6% for severe
sepsis.9 These numbers translate into approximately
750,000 new episodes of severe sepsis, with an annual mor-
tality rate of 220,000 (29%) in the US. It is the tenth most
common cause of death in the US, more so even than Ac-
quired Immune Deficiency Syndrome, breast cancer, co-
lon cancer and a first episode of acute myocardium infarc-
tion.9,13 A French study found that septic shock was the rea-
son for ICU admission in 8.4% of cases, with a mortality
rate of 60%.14 Recently, “Sepsis Occurrence in Acutely Ill
Patients (SOAP)” in Europe reported more than 35% of
ICU patients meet sepsis criteria during their ICU stay, with
a mortality rate of 27%.17
Silva et al., in the “Brazilian Sepsis Epidemiological
Study (BASES study)”,11 evaluated 1383 consecutive patients
in 5 ICUs of tertiary care hospitals distributed over two dif-
ferent regions of the country. They collected daily data on
SIRS, sepsis, severe sepsis and septic shock. The median age
was 65.2 years-old, and the overall 28-day mortality rate was
21.8%. The incidence density for sepsis, severe sepsis and
septic shock were 61.4, 35.6 and 30.0 per 1000 patient-days,
respectively. The mortality rates were 24.3% (SIRS), 34.7%
(sepsis), 47.3% (severe sepsis) and 52.2% (septic shock). The
respiratory tract was the most common source of infection.8,11
This study also showed that there are important regional dif-
ferences in mortality rates, as well as differences related to
the type of hospital administration (public or private). This
was accounted for by the fact that Brazil is a continental
country with a heterogeneous population and unequal access
to health care facilities; thus, social factors may play a more
significant role in determining infection patterns and mor-
tality of septic patients. These findings suggest that issues
related to the care of septic patients need to be discussed by
the whole society.11
The recent microbiological patterns of infections that
cause septic shock and severe sepsis have changed signifi-
cantly. Gram-negative bacteria used to be the most frequent
germs involved in the pathogenesis of these syndromes.
However, Gram-positive bacteria are currently as common
as Gram-negative, and fungi are also responsible for a large
portion of infections. It is not possible to isolate a patho-
gen in about a third of sepsis episodes; in some patients, it
is difficult to obtain material for culture. Cultures are of-
ten not positive after the initiation of antibiotics.2,8,9,13,14
Upward trends in sepsis incidence and patient survival
are consistent in the medical literature; however, more peo-
ple are exposed every year, and the total number of deaths
is actually increasing. Patients who have met diagnostic
criteria for severe sepsis and septic shock have higher over-
all mortality rates than other critically ill patients.
PATHOPHYSIOLOGY
Sepsis describes a complex clinical syndrome that de-
velops when the initial, appropriate host response to an in-
fection becomes amplified and then dysregulated. Determin-
ing the structural components of the bacteria that are respon-
sible for initiating the septic process has been important, not
only in understanding the underlying mechanisms, but also
in identifying potential therapeutic targets. These bacterial
motifs, which are recognized by the innate immune system,
have been called pathogen-associated molecular patterns
(PAMPs), although it might be more accurate to call them
microorganism-associated molecular patterns as it is by no
means clear how the host distinguishes between signals from
pathogens and commensals.18,19 In Gram-negative bacteria,
lipopolysaccharide (LPS; known also as endotoxin) plays a
dominant role. LPS is embedded in the outer membrane, and
the lipid A portion of the molecule anchors LPS in the bac-
terial cell wall. Conformational changes of LPS seem to cor-
relate with its ability to activate host cell membranes. There
is no endotoxin in Gram-positive bacteria, but an important
feature is the production of potent exotoxins. These Gram-
positive exotoxins are of great interest because they exhibit
the properties of superantigens, that is, they are able to bind
promiscuously to major histocompatibility complex class II
and a restricted repertoire of T-lymphocyte receptor (TCR)
Vb domains. In so doing, they cause massive T-cell activa-
tion and release of pro-inflammatory lymphokines. The best
known examples are toxic shock syndrome caused by toxic
shock syndrome toxin-1 (TSST-1)-producing strains of Sta-
phylococcus aureus and the pyrogenic exotoxins from Strep-
tococcus pyogenes. Peptidoglycan and lipoteichoic acid from
the gram-positive cell walls can bind to cell-surface receptors
and are pro-inflammatory, although they are much less ac-
tive on a weight-for-weight basis than LPS. Their role in the
pathogenesis of clinical sepsis remains uncertain.20,21,22
Host recognition of microbial components
The inability to identify an ‘LPS receptor’ was for many
years a barrier to understanding how Gram-negative bac-
112
CLINICS 2008;63(1):109-20Sepsis: from bench to bedside
Silva E et al.
teria initiate the septic response; activation of host cell is
dependent on the presence of LPS-binding protein (LBP)
and the opsonic receptor CD14. Although CD14 was origi-
nally identified as the essential co-receptor that mediated
LPS activation of monocytes, subsequent work has shown
that it also participates in the activation by Gram-positive
cell wall components, such as peptidoglycan, mediates
macrophage apoptosis and is important in shuttling LPS
between serum proteins that have the capacity to bind LPS,
such as LBP and serum lipoproteins.23, 33
Although the discovery of CD14 represented a signifi-
cant step forward in understanding host responses to LPS,
the fact that mCD14 had no intracellular tail meant that it
remained unclear how ligation of the LPS–LBP complex
led to cellular activation. This uncertainty was resolved by
the discovery of the family of Toll-like receptors (TLRs).
The TLRs have an intracellular domain that is homologous
with the IL-1 and IL-18 receptors. Adapter proteins facili-
tate binding to IL-1 receptor-associated kinase, which in
turn induces TNF receptor-associated factor-6, leading to
nuclear translocation of nuclear factor-κB (NF-κB) and ul-
timately to activation of cytokine gene promoters.24, 25
A family of (currently) ten TLRs has been identified
with a wide range of ligand specificity, including bacte-
rial, fungal and yeast proteins. Thus, TLR4 is the LPS
receptor, TLR2 is predominantly responsible for recogniz-
ing Gram-positive cell-wall structures, TLR5 is the receptor
for flagellin and TLR9 recognizes CpG elements in bacte-
rial DNA25, 26, 27.
An additional layer of complexity has been provided
by the discovery that there are several additional pathways
by which cells recognize microbial components. The trig-
gering receptor expressed on myeloid cells (TREM-1) and
the myeloid DAP12-associating lectin (MDL-1) are two
recently identified receptors involved in monocytic activa-
tion and inflammatory response. TREM-1 is upregulated
in the presence of various microorganisms, although its lig-
and unknown28, 29, 30. Monocytic intracellular proteins NOD1
and NOD2 (for nucleotide-binding oligomerization do-
main), which seem to have the ability to bind to and con-
fer responsiveness to LPS, were recently described. Geno-
typic variations in NOD2 might be associated with
phenotypic variations in LPS responsiveness. Peptidogly-
can-recognition proteins (PGRPs) were identified in moths,
and a family of PGRP genes was subsequently found in
humans. Different PGRPs can distinguish between Gram-
positive and Gram-negative bacteria31, 32.
Signal amplification
Following the initial host–microbial interaction, there
is widespread activation of the innate immune response,
which coordinates a defensive response involving both hu-
moral and cellular components33. Mononuclear cells release
the classic pro-inflammatory cytokines IL-1, IL-6 and TNF-
α, but in addition, an array of other cytokines, including
IL-12, IL-15 and IL-18, and a host of other small molecules
are released. TNF-α and IL-1 are the prototypic inflam-
matory cytokines that mediate many of the immunopatho-
logical features of LPS-induced shock. They are released
during the first 30-90 minutes after exposure toLPS, acti-
vate a second level of inflammatory cascades in turn, in-
cluding cytokines, lipid mediators and reactive oxygen spe-
cies and up-regulate cell adhesion molecules, which initi-
ates inflammatory cell migration into tissues.34, 35.
One of the most intriguing concepts related to host rec-
ognition and signal amplification after a challenge with
microbes is tolerance. Exposure of macrophages to LPS or
other proinflammatory stimuli, such as cytokine TNF-α,
can induce a state of tolerance, in which reduced activa-
tion is found upon subsequent exposure to LPS or the
proinflammatory mediator. Among the proposed mecha-
nisms, reduced TLR expression has been speculated.
Brunialti et al.36 have elegantly demonstrated that the ex-
pression of TLRs 2 and 4 in monocytes from septic patients
is preserved, although they found a lower production of
cytokines after inflammatory stimuli. These findings sug-
gest that the down-regulation observed in patients with se-
vere sepsis and septic shock appears to be related to intra-
cellular pathways and not due to TLR expression. Indirect
evidence from the authors had already demonstrated this,
using biotinylated LPS and flow cytometry to study LPS-
monocyte interaction and LPS-induced cellular activation
in whole blood from septic patients37. Furthermore, the
same group38 has demonstrated that neutrophils from sep-
tic patients preserve their capacity for phagocytosis and
generate reactive oxygen species. Taken together, these
findings suggest that tolerance is a phenomenon linked to
macrophage response and is not related to TLR expression.
More recently, a novel cytokine has been extensively
evaluated. High mobility group B1 (HMGB1) has been
identified as a cytokine-like product of macrophages that
appears much later after LPS stimulation. It stabilizes
nucleosomes, facilitates gene transcription and modulates
the activity of steroid hormone receptors39. Subsequently,
patients with sepsis have elevated serum levels of HMGB1,
and higher levels, in some studies are associated with an
increased mortality, suggesting that clinical intervention by
blocking or neutralizing HMGB1 might be a viable treat-
ment option41, 42. Recently, we have shown that neutrophils
from volunteers and septic patients show a different pat-
tern of gene expression after culture with HMGB1. How-
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ever, neutrophils from septic patients preserve intracellu-
lar activation and express proinflammatory genes, suggest-
ing that neutrophils are not anergic or tolerant, in contrast
to macrophages42. These data are in agreement with those
mentioned before.
Another macrophage-derived cytokine that has been
identified as a potential therapeutic target in sepsis is mac-
rophage migration inhibitory factor (MIF). It mediates
shock caused by Gram-positive and Gram-negative bacte-
ria. MIF has a curious relationship with glucocorticoids,
which are normally thought of as being anti-inflammatory,
because low doses of glucocorticoids paradoxically induce
macrophage MIF. Once released, MIF then acts as a
proinflammatory agent, overriding the ability of
glucocorticoids to prevent shock in animal models of sep-
sis43,44,45.
Neutrophil migration
Neutrophils have a dual role in sepsis. On one hand,
these cells are crucial for local control of bacterial growth
and, consequently, for the prevention of bacterial dissemi-
nation. On the other hand, neutrophils play an important
role in the endothelial activation and organ failure devel-
opment. Cunha’s group has advocated that impaired neu-
trophil migration to the infectious focus is associated with
high mortality and increased numbers of bacteria in peri-
toneal exudate and blood in a cecal-ligation and puncture
CLP model in rats. Conversely, in sublethal sepsis, neu-
trophil migration was not suppressed, and the bacterial in-
fection was restricted to the peritoneal cavity; consequently,
no significant mortality was observed. This group has also
addressed the mechanisms of neutrophil migration impair-
ment. They have demonstrated that the nitric oxide path-
way46 and TLR signaling47 are both involved in this proc-
ess.
The coagulation cascade
Cytokines are also important in inducing a procoagulant
effect in sepsis. Coagulation disorders are common in sep-
sis, and 30–50% of patients have the more severe clinical
form, disseminated intravascular coagulation. Coagulation
pathways are initiated by LPS and other microbial com-
ponents, inducing expression of tissue factor in mononu-
clear and endothelial cells. Tissue factor activates a series
of proteolytic cascades that result in the conversion of pro-
thrombin to thrombin, which in turn generates fibrin from
fibrinogen. Simultaneously, normal regulatory fibrinolytic
mechanisms (fibrin breakdown by plasmin) are impaired
because of high plasma levels of plasminogen-activator in-
hibitor type-1 (PAI-1) that prevent generating plasmin from
the precursor plasminogen. The net result is enhanced pro-
duction and reduced removal of fibrin, leading to the depo-
sition of fibrin clots in small blood vessels, impairing tis-
sue perfusion and organ function. Proinflammatory
cytokines, in particular IL-1 and IL-6, are powerful induc-
ers of coagulation; conversely, IL-10 regulates coagulation
by inhibiting the expression of tissue factor in monocytes.
An additional cause of the procoagulant state in sepsis is
the down-regulation of three naturally occurring anticoagu-
lant proteins: antithrombin, protein C and tissue factor path-
way inhibitor48, 49, 50. These natural anticoagulants are of par-
ticular interest because they have anti-inflammatory prop-
erties in addition to their effect on thrombin generation.
These effects include the release of monocyte-derived TNF-
α by inhibiting activation of the transcription factors NF-
κB and activator protein (AP)-1. Particular attention has
focused on Protein C, which is converted to the activated
form (aPC) when thrombin complexes with thrombomo-
dulin, an endothelial transmembrane glycoprotein. Once
aPC is formed, it dissociates from an endothelial protein
C receptor (EPCR) before binding protein S, resulting in
inactivation of factors Va and VIIIa and, thus, blockade of
the coagulation cascade. It has been shown recently that
aPC uses EPCR as a co-receptor for cleavage of protease-
activated receptor 1 (PAR1). Gene profiling showed that
PAR1 signaling could account for the activation of aPC-
induced protective genes, including the immunomodulatory
monocyte chemoattractant protein-1 (MCP-1), which sug-
gests a role for PAR-1 activation in protection from sep-
sis. In septic patients, aPC levels are reduced, and expres-
sion of endothelial thrombomodulin and EPCR are im-
paired, providing some support for the notion that replace-
ment of aPC might have therapeutic value51, 52.
The counter-inflammatory response
The profound proinflammatory response that occurs in
sepsis is balanced by an array of counter-regulatory mol-
ecules that attempt to restore immunological equilibrium.
Counter-inflammatory cytokines include antagonists such as
the soluble TNF receptors and IL-1 receptor antagonist, de-
coy receptors such as IL-1 receptor type II, inactivators of
the complement cascade and anti-inflammatory cytokines,
of which IL-10 is the prototype. In concert with this, the host
response to injury includes profound changes in metabolic
activity (increased cortisol production and release of
catecholamines), induction of acute-phase proteins and en-
dothelial activation with upregulation of adhesion molecules
and release of prostanoids and platelet-activating factor
(PAF). Another facet of down-regulation of immunity that
114
CLINICS 2008;63(1):109-20Sepsis: from bench to bedside
Silva E et al.
occurs in sepsis is the development of lymphocyte apoptosis;
subset analysis of autopsy tissue samples has shown that
there is selective depletion of B and CD4+ lymphocytes. This
process and its functional consequences are viewed as part
of a more general state of immunosuppression, character-
ized by T-cell hypo-responsiveness and anergy, which oc-
curs to some extent in most septic patients and is seen as a
counter-balancing response (and sometimes, over-response)
to the initial proinflammatory state. It is because of this over-
response that some investigators view the counter-inflamma-
tory response as the cause of an inadequate host defense
against infection and thus as a potential ‘mediator’ of sepsis
and progressive organ failure. Several researchers have pur-
sued the notion that reversal of this immunosuppressive state
might be of therapeutic value. For instance, mice transfected
with the human gene bcl-2, which overexpresses the anti-
apoptotic protein Bcl-2, are protected from death after cae-
cal ligation and puncture, and patients that received IFN-γ
in a small, nonrandomized clinical study showed up-regula-
tion of HLA-DR in their monocytes and a better-than-an-
ticipated survival.53
Mechanisms of organ failure
The ultimate cause of death in patients with sepsis is
multiple organ failure. There is a close relationship between
the severity of organ dysfunction on admission to an ICU
and the probability of survival and between the numbers of
organs failing and the risk of death. The mechanisms involve
widespread fibrin deposition that causes microvascular oc-
clusion, the development of tissue exudates that further com-
promise adequate oxygenation and disorders of microvascu-
lar homeostasis that result from the elaboration of vasoac-
tive substances such as PAF, histamine and prostanoids. Cel-
lular infiltrates, particularly neutrophils, damage tissue di-
rectly by releasing lysosomal enzymes and superoxide-de-
rived free radicals. TNF-α and other cytokines increase the
expression of inducible nitric oxide synthase, and increased
production of nitric oxide causes further vascular instabil-
ity and may also contribute to the direct myocardial de-
pression that occurs in sepsis.54, 55, 56 The tissue hypoxia that
develops in sepsis is reflected in the oxygen debt, i.e., the
difference between oxygen delivery and oxygen require-
ments. The extent of the oxygen debt is related to the out-
come from sepsis, and strategies designed to optimize oxy-
gen delivery to the tissues can improve survival57. In addi-
tion to hypoxia, cells may be dysoxic; i.e., unable to prop-
erly utilize available oxygen. Recent data suggest that this
may be another consequence of excess nitric oxide produc-
tion because skeletal muscle biopsies from septic patients
show evidence of impaired mitochondrial respiration, which
is inhibited by nitric oxide58, 59. Cross-talk between cytokines
and neurohormones is the cornerstone of restoration of ho-
moeostasis during stress. Production and release of vaso-
pressin and corticotropin-releasing hormone are enhanced by
circulating TNF and interleukins-1, -6 and -2, by locally ex-
pressed interleukin 1 and NO and by afferent vagal fibers.
Moreover, cortisol synthesis is modulated by locally ex-
pressed interleukin-6 and TNF-α. Up-regulated hormones
help maintain cardiovascular homoeostasis and cellular me-
tabolism and contain foci of inflammation. Impaired endo-
crine responses to sepsis might result from cytokines, neu-
ronal apoptosis, metabolic and ischemic derangements in the
hypothalamic-pituitary and adrenal glands or drug adminis-
tration. Deficiencies in adrenal gland function and vaso-
pressin production occur in about a half and a third of sep-
tic shock cases, respectively, and contribute to hypotension
and death. Other endocrine disorders during sepsis have un-
clear mechanisms and consequences60, 61.
Genetic polymorphisms
Among this vast array of host molecules that orches-
trate the response to sepsis, there are many examples of
genetic variability that influence physiological activity.
Various genetic polymorphisms are associated with in-
creased susceptibility to infection and poor outcomes.
Markers of susceptibility could include single nucleotide
polymorphisms of genes encoding cytokines (e.g., TNF,
lymphotoxin-α, interleukin-10, interleukin-18, interleukin-
1 receptor antagonist, interleukin 6 and interferon α), cell
surface receptors (e.g., CD14, MD2, toll-like receptors 2
and 4 and Fc-gamma receptors II and III), lipopolysaccha-
ride ligand (lipopolysaccharide binding protein, bactericidal
permeability increasing protein), mannose-binding lectin,
heat shock protein 70, angiotensin I-converting enzyme,
plasminogen activator inhibitor and caspase-12. Use of
genotype combinations could improve the identification of
high-risk groups62, 63, 64, 65.
THERAPEUTIC APPROACHES
Despite the extraordinary developments in understand-
ing the immunopathology of sepsis, therapeutic advances
have been painfully slow. Septic shock remains a major
source of both short- and long-term morbidity and mortal-
ity and places a large burden on the healthcare system66.
The recent identification of molecules in humans that sense
microbial determinants has been an important step in un-
derstanding the molecular and cellular basis of sepsis. Char-
acterizing the links between inflammation, coagulation and
the immune and neuroendocrine systems has led to the de-
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velopment of international guidelines. New knowledge
about apoptosis, leukocyte reprogramming, epithelial dys-
function and factors involved in sepsis holds promise for
the development of new therapeutic approaches. A group
of international critical care and infectious disease clini-
cians, experts in the diagnosis and management of infec-
tion and sepsis who represent 11 organizations, came to-
gether to develop guidelines that the bedside clinician could
use to improve outcome in severe sepsis and septic shock.
This process represented phase II of the Surviving Sepsis
Campaign, an international effort to increase awareness and
improve outcomes in severe sepsis67.
Besides guidelines, the Severe Sepsis Bundles are de-
signed to allow teams to follow the timing, sequence and
goals of the individual elements of care in order to achieve
the goal of a 25% reduction in mortality from severe sep-
sis (Table 3). Individual hospitals should use the bundles
to create customized protocols and pathways specific to
their institutions. However, all of the elements in the bun-
dles must be incorporated in these protocols. The addition
of other strategies not found in the bundles is not recom-
mended. The bundle will form the basis for the measure-
ments that improvement teams will conduct to follow hos-
pitals’ progress as they make changes. Hospitals should
implement two different Severe Sepsis Bundles. Each bun-
dle articulates requirements for specific timeframes.
• Sepsis Resuscitation Bundle: Tasks that should begin
immediately but must be done within 6 hours for pa-
tients with severe sepsis or septic shock.
• Sepsis Management Bundle: Tasks that should begin
immediately but must be done within 24 hours for pa-
tients with severe sepsis or septic shock.67, 68
Initial Resuscitation
The resuscitation of a patient with severe sepsis or sep-
sis-induced tissue hypoperfusion should begin as soon as
the syndrome is recognized. An elevated serum lactate con-
centration identifies tissue hypoperfusion in patients at risk
who are not hypotensive. During the first 6 hrs of resusci-
tation, the goals of initial resuscitation of sepsis-induced
hypoperfusion should include all of the following as one
part of a treatment protocol:
Central venous pressure (CVP): 8–12 mm Hg,
Mean arterial pressure (MAP): ≥ 65 mm Hg,
Urine output: ≥ 0.5 mL·kg-1·hr-1 and
Central venous (superior vena cava) or mixed venous oxy-
gen saturation: ≥ 70%68, 69.
Predictive factors of fluid responsiveness have been
evaluated in order to select patients who might benefit from
volume expansion and avoid ineffective or even deleteri-
ous volume expansion. There is a minimal value of static
ventricular preload parameters, and the use of dynamic pa-
rameters in the decision-making process is more effective
concerning volume expansion. In sedated patients receiv-
ing mechanical ventilation in a volume-controlled mode
with a tidal volume of at least 8 ml/kg with acute circula-
tory failure related to sepsis, the use of pulse pressure vari-
ation is an accurate indicator of fluid responsiveness70.
Diagnosis
Appropriate cultures should always be obtained before
antimicrobial therapy is initiated. Two blood cultures
should be obtained, with at least one drawn percutaneously
and one drawn through each vascular access device, un-
less the device was recently (<48 hrs) inserted. Cultures
from other sites should be obtained before antibiotic
therapy is initiated as the clinical situation dictates71, 72, 73.
Antibiotic Therapy
Intravenous antibiotic therapy should be started within
the first hour (and should be reasonable until the third hour)
that severe sepsis is recognized, after appropriate cultures
have been obtained. Establishing a supply of premixed
antibiotics is an appropriate strategy to enhance the likeli-
hood that antimicrobial agents will be infused promptly.
The initial selection of an empirical antimicrobial regimen
Table 3 - Severe Sepsis Bundles
Sepsis Resuscitation Bundle
(To be accomplished as soon as possible and scored over the first 6 hours):
1. Measure serum lactate.
2. Obtain blood cultures prior to antibiotic administration.
3. From the time of presentation, administer broad-spectrum antibiotics
within 3 hours for ED admissions and 1 hour for non-ED ICU admissions.
4. In the event of hypotension and/or lactate > 36 mg/dL:
a) Deliver an initial minimum of 20 mL/kg of crystalloid (or colloid
equivalent).
b) Apply vasopressors for hypotension that does not respond to initial
fluid resuscitation to maintain mean arterial pressure (MAP) > 65 mm
Hg.
5. In the event of persistent hypotension despite fluid resuscitation (septic
shock) and/or lactate > 4 mmol/L (36 mg/dL):
a) Achieve central venous pressure (CVP) of > 8 - 12mmHg.
b) Achieve central venous oxygen saturation (ScvO2) of > 70%.
Sepsis Management Bundle
(To be accomplished as soon as possible and scored over the first 24 hours):
1. Administer low-dose steroids for septic shock in accordance with a
standardized ICU policy.
2. Administer drotrecogin alfa (activated) in accordance with a standardized
ICU policy.
3. Glucose control maintained above lower limit of normal, but < 150 mg/
dl.
4. Maintain inspiratory plateau pressures at < 30 cm H2O for mechanically
ventilated patients.
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should be sufficiently broad; there is ample evidence that
failure to initiate appropriate therapy promptly has adverse
consequences on outcome. All patients should receive an
initial full loading dose of each antimicrobial. De-escala-
tion antibiotic therapy should be tailored according to clini-
cal status, severity of illness and culture results73, 74,75.
Source Control
Every patient presenting with severe sepsis should be
evaluated for the presence of a focus on infection amena-
ble to source control measures; specifically, the drainage
of an abscess or local focus of infection, the debridement
of infected necrotic tissue, the removal of a potentially in-
fected device or the definitive control of a source of ongo-
ing microbial contamination76, 77.
Fluid Therapy
Fluid resuscitation may consist of natural or artificial
colloids or crystalloids. There is no evidence-based sup-
port for one type of fluid over another. As the volume of
distribution is much larger for crystalloids than for colloids,
resuscitation with colloids requires less fluid to achieve the
same end points. Fluid challenge in patients with suspected
hypovolemia may be given at a rate of 500–1000 mL of
crystalloids or 300–500 mL of colloids over 30 min and
repeated on the basis of response (e.g., increase in blood
pressure and urine output) and tolerance (e.g., evidence of
intravascular volume overload)78, 79,80.
In animal models, ethyl pyruvate (EP) reduces organ
system damage in ischemia/reperfusion injury and
hemorrhagic and endotoxic shock, at least in part through
its antioxidant action. In addition, EP appears to have di-
rect beneficial effects on cytokine expression and
proinflammatory gene regulation. These findings could be
a rationale for the use of EP in septic patients; however,
more studies are needed to support its use81.
Our group has tested the hypothesis that a hypertonic so-
lution could be an alternative solution for sepsis. In a previ-
ous study, we found that an early, large volume of crystal-
loid after live Escherichia coli injection in dogs promoted
partial and transient benefits during the fluid infusion, which
were especially poor at the splanchnic bed82, 83. Subsequently,
we have tested the hypothesis that hypertonic solution (HS)
infusion promotes better systemic and regional benefits than
conventional isotonic crystalloid infusion in experimental
sepsis (infusion of E. coli at a dose of 1.2 × 1010 cfu/kg). A
large volume of Lactated Ringer’s solution or a small vol-
ume of HS promoted similar transient hemodynamic ben-
efits that were unable to restore sepsis-induced perfusional
deficits. However, a single bolus of HS did promote sustained
systemic and mesenteric oxygen extraction reductions with-
out deterioration of perfusional markers such as lactate lev-
els and pCO2 gradients84. A clinical trial should be carried
out to validate these findings.
Vasopressors
When an appropriate fluid challenge fails to restore ad-
equate blood pressure and organ perfusion, therapy with
vasopressor agents should be started. Use of an arterial
catheter provides a more accurate and reproducible meas-
urement of arterial pressure. Either norepinephrine or
dopamine (through a central catheter as soon as available)
is the first-choice vasopressor agent for correcting hypo-
tension in septic patients. Low-dose dopamine should not
be used for renal protection as part of the treatment of se-
vere sepsis. Vasopressin use may be considered in patients
with refractory shock despite adequate fluid resuscitation
and high-dose conventional vasopressors. It should be ad-
ministered at infusion rates of 0.01–0.04 units/min85, 86.
Inotropic Therapy
In patients with low cardiac output despite adequate
fluid resuscitation, dobutamine may be used to increase
cardiac output. If used in the presence of low blood pres-
sure, it should be combined with vasopressor therapy. A
strategy of increasing cardiac index to achieve an arbitrar-
ily predefined elevated level is not recommended87.
Steroids
Intravenous corticosteroids (e.g., hydrocortisone, 200–
300 mg/day for 7 days in three or four divided doses or by
continuous infusion) are suggested in patients with septic
shock who respond poorly to both fluid replacement and
vasopressors. Some experts would use a 250 µg adrenocor-
ticotropic hormone ACTH stimulation test to identify re-
sponders (i.e., >9 µg/dL increase in plasmatic cortisol 30–
60 min post-ACTH administration) and discontinue therapy
in these patients88. However, in a recent trial (CORTICUS),
the ACTH test was not able to discriminate patients who
will eventually respond to steroid treatment. Hence, this
test has been discouraged. Because hydrocortisone has in-
trinsic mineralocorticoid activity, there is controversy as to
whether fludrocortisone should be added.
A post hoc analysis of the effect of treatment with low
doses of hydrocortisone and fludrocortisone on mortality
in patients with septic shock showed that a 7-day treatment
with low doses of corticosteroids was associated with bet-
117
CLINICS 2008;63(1):109-20 Sepsis: from bench to bedside
Silva E et al.
ter outcomes in septic shock-associated early ARDS non-
responders but not in responders or in septic shock patients
without ARDS89,90,91.
Recombinant Human Activated Protein C (rhAPC)
Using rhAPC is suggested in patients at high risk of
death (e.g., APACHE II ≥ 25, sepsis-induced multiple or-
gan failure, septic shock) and with no absolute contraindi-
cation related to bleeding risk or relative contraindication
that outweighs the potential benefit of rhAPC. The EN-
HANCE study has shown that patients treated within 0-24
hrs from their first sepsis-induced organ dysfunction had a
lower observed mortality rate than those treated after 24
hrs. The ADDRESS study indicated that rhAPC should not
be used in patients with severe sepsis who are at a low risk
for death, such as those with single-organ failure or an
APACHE II score less than 25. In these patients, there was
an absence of a beneficial treatment effect, coupled with
an increased incidence of serious bleeding.92, 93 More re-
cently, a new industry-funded randomized clinical trial has
been prepared to test the efficacy of rhAPC infusion only
in high-risk septic patients.
Mechanical Ventilation of Sepsis-Induced Acute Lung
Injury (ALI)/ARDS
High tidal volumes that are coupled with high plateau pres-
sures should be avoided in ALI and/or ARDS; the goal is a
reduction in tidal volumes over 1–2 hrs to a “low” tidal vol-
ume (i.e., 6 mL per kilogram of predicted body weight) in
conjunction with end-inspiratory plateau pressures <30
cmH2O. Hypercapnia can be tolerated in order to minimize
plateau pressures and tidal volumes. The use of hypercarbia
is limited in patients with preexisting metabolic acidosis and
is contraindicated in patients with increased intracranial pres-
sure. A minimum amount of positive end-expiratory pressure
should be set to prevent lung collapse at end-expiration. Set-
ting positive end-expiratory pressure based on the severity of
the oxygenation deficit and guided by the FiO2 required to
maintain adequate oxygenation is one acceptable approach.
Some experts titrate positive end-expiratory pressure accord-
ing to bedside measurements of thoracopulmonary compliance
in order to obtain the highest compliance, reflecting lung re-
cruitment94, 95, 96, 97. One trial has shown that, in patients with
ALI and ARDS who receive mechanical ventilation with a
tidal-volume goal of 6 mL per kilogram of predicted body
weight and an end-inspiratory plateau-pressure limit of 30 cm
of water, clinical outcomes are similar whether lower or higher
positive end expiratory pressure (PEEP) levels are used98. The
currently suggested strategy of ventilation with low lung vol-
umes can aggravate lung collapse and potentially produce lung
injury through shear stress at the interface between aerated
and collapsed lung, as a result of repetitive opening and clos-
ing of alveoli. An ‘open lung strategy’ focused on alveolar pa-
tency has therefore been recommended. In animal studies, re-
cruitment maneuvers clearly reverse the derecruitment asso-
ciated with low tidal volume ventilation, improve gas ex-
change and reduce lung injury. Data regarding the use of re-
cruitment maneuvers in patients with ARDS show mixed re-
sults, with increased efficacy in those with a short duration
of ARDS, good chest wall compliance, and extrapulmonary
ARDS. More data are needed to support this strategy102,103.
In experienced facilities, prone positioning should be
considered in ARDS patients who require potentially inju-
rious levels of FiO2 or plateau pressure who are not at high
risk for adverse consequences of positional changes100.
A weaning protocol should be in place, and mechani-
cally ventilated patients should undergo a spontaneous
breathing trial to evaluate their ability to discontinue me-
chanical ventilation when they satisfy the following crite-
ria: a) arousable; b) hemodynamically stable (without va-
sopressor agents); c) no new potentially serious conditions;
d) low ventilatory and end-expiratory pressure require-
ments; and e) requiring levels of FiO2 that could be safely
delivered with a face mask or nasal cannula. If the sponta-
neous breathing trial is successful, extubation should be
considered101, 102, 103.
Glucose Control
Following initial stabilization of patients with severe
sepsis, blood glucose should be maintained at <150 mg/
dL. Studies supporting the role of glycemic control have
used continuous infusion of insulin and glucose. With this
protocol, glucose should be monitored frequently after ini-
tiation of the protocol (every 30–60 min) and on a regular
basis (every 4 hrs) once the blood glucose concentration
has stabilized. A large single-center trial of postoperative
surgical patients showed significant improvement in sur-
vival when continuous-infusion insulin was used to main-
tain glucose between 80 and 110 mg/dL104. Another trial
in a medical ICU showed that intensive insulin therapy sig-
nificantly reduced morbidity but not mortality. Although the
risk of subsequent death and disease was reduced in patients
treated for three or more days, these patients could not be
identified before therapy105, 106.
CONCLUSION
Sepsis syndromes are still a daily challenge for
intensivists all over the world. Despite great improvements
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in the understanding of epidemiology, pathophysiology and
genetic predisposition to sepsis, both morbidity and mortal-
ity associated with severe sepsis and septic shock remain
unacceptably high. Recent efforts aiming to provide a frame-
work of uniform definitions and terms have been performed
in order to facilitate communication, research and patient
care. There has been progress in clinical management based
on widely known guidelines, and interventions targeting spe-
cific pathologic pathways have led to important break-
throughs, as well as some deceptions. In the future, we hope
that it will be possible to tailor treatment strategies based
on knowledge of an individual’s genetic profile,
comorbidities and phenotypic expressions derived from en-
vironmental influences and host-pathogen interactions.
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